tiprankstipranks
Blurbs

Goldman Sachs Keeps Their Buy Rating on Guardant Health (GH)

In a report released today, Matthew Sykes from Goldman Sachs maintained a Buy rating on Guardant Health (GHResearch Report), with a price target of $45.00. The company’s shares opened today at $31.38.

According to TipRanks, Sykes is an analyst with an average return of -14.0% and a 39.62% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Guardant Health, Agilent, and Exact Sciences.

Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $64.78.

See today’s best-performing stocks on TipRanks >>

GH market cap is currently $3.27B and has a P/E ratio of -5.38.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.

Read More on GH:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles